BRPI0604577A - dispositivo biodegradável para administração intra-ocular de fármacos - Google Patents

dispositivo biodegradável para administração intra-ocular de fármacos

Info

Publication number
BRPI0604577A
BRPI0604577A BRPI0604577-4A BRPI0604577A BRPI0604577A BR PI0604577 A BRPI0604577 A BR PI0604577A BR PI0604577 A BRPI0604577 A BR PI0604577A BR PI0604577 A BRPI0604577 A BR PI0604577A
Authority
BR
Brazil
Prior art keywords
biodegradable device
drug administration
biodegradable
formulation
drugs
Prior art date
Application number
BRPI0604577-4A
Other languages
English (en)
Inventor
Armando Da Solva Junior Cunha
Rubens Camargo Siqueira
Silvia Ligorio Fialho
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0604577A priority Critical patent/BRPI0604577B8/pt
Priority to PCT/BR2007/000222 priority patent/WO2008025111A2/en
Publication of BRPI0604577A publication Critical patent/BRPI0604577A/pt
Publication of BRPI0604577B1 publication Critical patent/BRPI0604577B1/pt
Publication of BRPI0604577B8 publication Critical patent/BRPI0604577B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

DISPOSITIVO BIODEGRADáVEL PARA ADMINISTRAçãO INTRA-OCULAR DE FáRMACOS A presente invenção diz respeito a processo de produção de formulação farmacêutica capaz de tratar degenerações retinianas e doenças do segmento posterior do bulbo do olho, tais como retinopatia diabética; degeneração macular ligada à idade; retinite por citomegalovírus; endoftalmite; uveítes. A dita formulação compreende um sistema monolítico do ativo composta por uma matiz é base de polímero biodegradável da classe dos poli-ésteres. A formulação é aplicável é administração pela via intra-ocular. O dispositivo biodegradável em questão pode veicular um ou mais fármacos das classes dos corticóides, como a dexametasona, a prednisolona e a triancinolona, antiinflamatórios não esteroidais, antibióticos, agentes imunossupressores, como a ciclosporina e o tacrolimus e agentes antiproliferativos.
BRPI0604577A 2006-08-31 2006-08-31 formulação farmacêutica para administração intraocular de fármacos e processo de obtenção BRPI0604577B8 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0604577A BRPI0604577B8 (pt) 2006-08-31 2006-08-31 formulação farmacêutica para administração intraocular de fármacos e processo de obtenção
PCT/BR2007/000222 WO2008025111A2 (en) 2006-08-31 2007-08-31 Biodegradable device for intraocular drug delivery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0604577A BRPI0604577B8 (pt) 2006-08-31 2006-08-31 formulação farmacêutica para administração intraocular de fármacos e processo de obtenção

Publications (3)

Publication Number Publication Date
BRPI0604577A true BRPI0604577A (pt) 2008-04-22
BRPI0604577B1 BRPI0604577B1 (pt) 2020-11-24
BRPI0604577B8 BRPI0604577B8 (pt) 2021-05-25

Family

ID=38987981

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0604577A BRPI0604577B8 (pt) 2006-08-31 2006-08-31 formulação farmacêutica para administração intraocular de fármacos e processo de obtenção

Country Status (2)

Country Link
BR (1) BRPI0604577B8 (pt)
WO (1) WO2008025111A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155585A1 (pt) * 2012-04-20 2013-10-24 Universidade Federal De Inas Gerais - Ufmg Dispositivo de liberação prolongada de talidomida e uso em doenças oculares causadoras de neovascularização

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588855B2 (en) * 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP6543431B2 (ja) * 2013-10-10 2019-07-10 ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 眼内薬物送達デバイスおよび付随する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155585A1 (pt) * 2012-04-20 2013-10-24 Universidade Federal De Inas Gerais - Ufmg Dispositivo de liberação prolongada de talidomida e uso em doenças oculares causadoras de neovascularização

Also Published As

Publication number Publication date
WO2008025111A2 (en) 2008-03-06
WO2008025111A3 (en) 2008-04-17
BRPI0604577B1 (pt) 2020-11-24
BRPI0604577B8 (pt) 2021-05-25
WO2008025111A8 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
Jinnah Diagnosis & treatment of dystonia
Shah et al. Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy
Semba et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye
Gialanella et al. Effects of corticosteroids injection in rotator cuff tears
Abelson et al. Advances in pharmacotherapy for allergic conjunctivitis
Nguyen et al. Intravitreal sirolimus for the treatment of noninfectious uveitis: evolution through preclinical and clinical studies
Bravo-Osuna et al. Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina
JP2002539245A (ja) 心的外傷後ストレス障害、強迫性障害および関連する神経精神医学的障害の処置
Balguri et al. Melt-cast noninvasive ocular inserts for posterior segment drug delivery
KR20210029849A (ko) 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
Stringham et al. Dropless cataract surgery: what are the potential downsides?
Vigil et al. Assessment of changes in quality of life among patients in the SAVE Study-Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis
Maleki et al. Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema
Torkildsen et al. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
Zhao et al. Sustained release of brimonidine from BRI@ SR@ TPU implant for treatment of glaucoma
Hovanesian et al. Intracameral dexamethasone 9% vs prednisolone acetate 1% in controlling postoperative pain and inflammation in patients undergoing cataract surgery
Donnenfeld et al. Safety and efficacy of nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation after cataract surgery
Fong et al. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery
WO2008025111A3 (en) Biodegradable device for intraocular drug delivery
JP2018516910A (ja) 神経外傷を制限するための処方物および方法
Ohguro et al. Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results
Pirouzian et al. Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery
Abdullah et al. Medication adherence, sensory attributes, and adverse effects of intranasal corticosteroids in allergic rhinitis patients: A systematic review and meta-analysis
CN104780917A (zh) 基于巴氯芬和阿坎酸的黄斑变性病症的疗法
Kartha Therapeutic challenges in dystonia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22L Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi)

Free format text: REFERENTE A PETICAO NO 870230033311 DE 20.04.2023 - O INTERESSADO PODERA OBTER COPIA NA INTEGRA DAS CONDICOES CONTRATUAIS OFERECIDAS PELO TITULAR (INSTRUCAO NORMATIVA NO 17/2013 ITEM 8), MEDIANTE PETICIONAMENTO ELETRONICO AO INPI - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI

B22L Other matters related to patents and certificates of addition of invention: notification of licence offer (art 64 par 1 of lpi)

Free format text: OFERTA DE LICENCA DE PATENTE - REFERENTE A PETICAO NO 870230033311 DE 20.04.2023 - O INTERESSADO PODERA OBTER COPIA NA INTEGRA DAS CONDICOES CONTRATUAIS OFERECIDAS PELO TITULAR (INSTRUCAO NORMATIVA NO 17/2013 ITEM 8), MEDIANTE PETICIONAMENTO ELETRONICO AO INPI - OBS: CONSULTA A CARTA PATENTE PODERA SER FEITA ATRAVES DO ENDERECO ELETRONICO WWW.INPI.GOV.BR - NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI.